Eris Lifesciences Q2 FY26 PAT jumps 39.5%, revenue up 7.2%

Profit growth above 25%EBITDA margin expansionResults restatedResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹1579.00

prior close

₹1592.90

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-0.9% vs market

Pharmaceuticals peers, median of 157sector+0.8%-0.9% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.6

15m

-0.4

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.7-0.9+0.8-0.9

Next day

-2.6+0.3-2.9+0.5-3.1

-1.8+0.5-2.4+0.4-2.2

-0.9+1.2-2.1+0.6-1.4

-0.7+0.2-0.9-0.1-0.6

+2.0-0.3+2.2-0.6+2.5

+5.1-1.6+6.7-1.2+6.3

15d

-0.8-2.2+1.4-1.8+1.0

-0.5-3.5+3.0-2.6+2.1

-5.2-5.3+0.1-5.4+0.2

-4.4-4.4+0.0-6.0+1.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences posted Q2 FY26 consolidated revenue of Rs 792.41 crore, up 7.2% YoY. Net profit surged 39.5% to Rs 134.47 crore. H1 FY26 revenue at Rs 1,565.41 crore and PAT at Rs 259.57 crore, up 39.6% YoY. Margins expanded with operating margin at 28% versus 25.5% last year. Auditor issued unmodified opinion. Board re-appointed Whole Time Director and an Independent Director for 5 years each.

Likely market impact

Strong profit growth and margin expansion are positive. Director re-appointments bring continuity. Healthy signals for shareholders.